IterOnco

Founded in 2024 and strategically located in the Paris-Saclay University Park, France, IterOnco is an innovative French biotechnology startup dedicated to advancing cancer treatment and enhancing clinical outcomes through innovation and quality services. Behind our mission is a passionate team of scientists, researchers, and professionals who are deeply committed to making a difference. Every day, we work diligently with the belief that our efforts can bring real hope and improved quality of life to patients and their loved ones. As specialists in oncology, we are dedicated to driving breakthroughs in cancer research and treatment through three core activities: 1. Innovative Research & Development At IterOnco, we are embarking on a promising journey to develop next-generation cancer therapies, with a particular focus on Natural Killer (NK) cell immunotherapy. Our R&D efforts are dedicated to exploring and advancing novel therapeutic strategies that hold the potential to offer new hope in the fight against cancer. 2. Comprehensive Scientific & Regulatory Consulting Services We offer broad scientific and regulatory services to accelerate your projects and navigate the complexities of the biotechnology landscape. From project management and data analysis to crafting impactful scientific publications, preparing regulatory documents, and securing funding, our expertise is your advantage. 3. Advanced Preclinical In Vitro Services (Launching in 2025) In 2025, we will expand our offerings to include specialized preclinical in vitro services. Our capabilities will encompass detailed studies on pharmacology, toxicity, efficacy, and the identification of mechanisms of action, providing invaluable insights for your therapeutic development. Join Us on the Journey to Transform Cancer Treatment: IterOnco is not just a company; it's a commitment to innovation and excellence in oncology. Partner with us to push the boundaries of what’s possible in cancer treatment.